Literature DB >> 20957391

Metabolic syndrome, adipokines and ghrelin in overweight and obese schoolchildren: results of a 1-year lifestyle intervention programme.

Carla Pedrosa1, Bruno M P M Oliveira, Isabel Albuquerque, Carlos Simões-Pereira, Maria Daniel Vaz-de-Almeida, Flora Correia.   

Abstract

The aim of this study was to evaluate the effect of a lifestyle intervention programme (nutrition and exercise counselling) on metabolic syndrome (MS) components, adipokines (leptin, adiponectin) and ghrelin levels in overweight children. A total of 61 overweight children aged 7-9 years (≥ 85th body mass index (BMI) percentile; 27 boys/34 girls) were randomly assigned and completed a 1-year individual (IT) or group-based treatment (GT). Anthropometric and biochemical parameters were assessed at baseline, at 6 months and at 1 year. Twenty-two normal weight children (<85th BMI percentile; 7-9 years old; 13 boys/nine girls) were also evaluated at baseline. Insulin resistance (IR) was determined by the homeostasis model assessment of IR (HOMA-IR). Overweight children presented significantly higher blood pressure, triglycerides, apolipoprotein B, insulin, HOMA-IR, leptin, C-reactive protein and homocysteine levels, while apolipoprotein A-I was significantly lower. At baseline, MS was present in ten overweight children, of which only five maintained it at 1 year. Leptin and ghrelin levels were associated with IR and MS components. MS was predicted by apolipoprotein A-I, insulin and pre-puberty. The lifestyle intervention led to a significant improvement in standard deviation score of BMI, waist circumference/height ratio and lipid profile. Changes in insulin, HOMA-IR, leptin and adiponectin were not significant. Ghrelin behaved differently between IT and GT. The GT intervention seems to be more successful, with a decrease in BMI Z-score and an improvement of metabolic parameters. In conclusion, overweight children have multiple risk factors associated with MS. A lifestyle intervention programme seems to be an effective mean for reducing obesity and MS components and improving adipokines concentrations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20957391     DOI: 10.1007/s00431-010-1316-2

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  47 in total

Review 1.  Adiponectin--a key adipokine in the metabolic syndrome.

Authors:  J P Whitehead; A A Richards; I J Hickman; G A Macdonald; J B Prins
Journal:  Diabetes Obes Metab       Date:  2006-05       Impact factor: 6.577

Review 2.  The metabolic syndrome in children and adolescents.

Authors:  Martha L Cruz; Michael I Goran
Journal:  Curr Diab Rep       Date:  2004-02       Impact factor: 4.810

3.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Authors: 
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

4.  The role of insulin in clustering of serum lipids and blood pressure in children and adolescents. The Cardiovascular Risk in Young Finns Study.

Authors:  O T Raitakari; K V Porkka; T Rönnemaa; M Knip; M Uhari; H K Akerblom; J S Viikari
Journal:  Diabetologia       Date:  1995-09       Impact factor: 10.122

5.  Hemodynamic and hormonal effects of human ghrelin in healthy volunteers.

Authors:  N Nagaya; M Kojima; M Uematsu; M Yamagishi; H Hosoda; H Oya; Y Hayashi; K Kangawa
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-05       Impact factor: 3.619

Review 6.  Ghrelin: a hormone regulating food intake and energy homeostasis.

Authors:  Mercedes Gil-Campos; Concepción María Aguilera; Ramón Cañete; Angel Gil
Journal:  Br J Nutr       Date:  2006-08       Impact factor: 3.718

7.  Comparison of metabolic syndrome prevalence using eight different definitions: a critical approach.

Authors:  Thomas Reinehr; Gideon de Sousa; André Michael Toschke; Werner Andler
Journal:  Arch Dis Child       Date:  2007-02-14       Impact factor: 3.791

Review 8.  Health consequences of obesity in youth: childhood predictors of adult disease.

Authors:  W H Dietz
Journal:  Pediatrics       Date:  1998-03       Impact factor: 7.124

Review 9.  Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases.

Authors:  T Yamauchi; T Kadowaki
Journal:  Int J Obes (Lond)       Date:  2008-12       Impact factor: 5.095

Review 10.  Adiponectin, type 2 diabetes and the metabolic syndrome: lessons from human genetic studies.

Authors:  Francis Vasseur; David Meyre; Philippe Froguel
Journal:  Expert Rev Mol Med       Date:  2006-11-20       Impact factor: 5.600

View more
  14 in total

1.  Changes in ghrelin and asymmetrical dimethylarginine in obese Mexican adolescents after six-month lifestyle intervention.

Authors:  Fengyang Huang; Blanca Estela del-Río-Navarro; José Alfredo Pérez Ontiveros; Eliseo Ruiz-Bedolla; Efraín Navarro-Olivos; Santiago Villafaña; Guadalupe Bravo; Enrique Hong
Journal:  Endocrine       Date:  2012-09-29       Impact factor: 3.633

2.  Ghrelin and PYY levels in adolescents with severe obesity: effects of weight loss induced by long-term exercise training and modified food habits.

Authors:  Carine Gueugnon; Fabienne Mougin; Nhu Uyen Nguyen; Malika Bouhaddi; Marie Nicolet-Guénat; Gilles Dumoulin
Journal:  Eur J Appl Physiol       Date:  2011-09-11       Impact factor: 3.078

3.  Metabolic syndrome in school children in mardin, South-eastern of Turkey.

Authors:  Betul Battaloglu Inanc
Journal:  Eurasian J Med       Date:  2014-08-26

4.  Multidisciplinary therapy reduces risk factors for metabolic syndrome in obese adolescents.

Authors:  Josiane Aparecida Alves Bianchini; Danilo Fernandes da Silva; Claudia Christina Sanchez Nardo; Idalina Diair Regla Carolino; Florencio Hernandes; Nelson Nardo
Journal:  Eur J Pediatr       Date:  2012-10-25       Impact factor: 3.183

5.  Evaluation of serum xenin and ghrelin levels and their relationship with nonalcoholic fatty liver disease and insulin resistance in obese adolescents.

Authors:  N Arslan; O Sayin; Y Tokgoz
Journal:  J Endocrinol Invest       Date:  2014-09-09       Impact factor: 4.256

6.  Reduction in BMI z-score and improvement in cardiometabolic risk factors in obese children and adolescents. The Oslo Adiposity Intervention Study - a hospital/public health nurse combined treatment.

Authors:  Magnhild L Pollestad Kolsgaard; Geir Joner; Cathrine Brunborg; Sigmund A Anderssen; Serena Tonstad; Lene Frost Andersen
Journal:  BMC Pediatr       Date:  2011-05-27       Impact factor: 2.125

7.  The impact of an intervention taught by trained teachers on childhood overweight.

Authors:  Rafaela Rosário; Bruno Oliveira; Ana Araújo; Oscar Lopes; Patrícia Padrão; André Moreira; Vítor Teixeira; Renata Barros; Beatriz Pereira; Pedro Moreira
Journal:  Int J Environ Res Public Health       Date:  2012-04-16       Impact factor: 3.390

Review 8.  Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from the age of 6 to 11 years.

Authors:  Emma Mead; Tamara Brown; Karen Rees; Liane B Azevedo; Victoria Whittaker; Dan Jones; Joan Olajide; Giulia M Mainardi; Eva Corpeleijn; Claire O'Malley; Elizabeth Beardsmore; Lena Al-Khudairy; Louise Baur; Maria-Inti Metzendorf; Alessandro Demaio; Louisa J Ells
Journal:  Cochrane Database Syst Rev       Date:  2017-06-22

9.  The effect of 'sleep high and train low' on weight loss in overweight Chinese adolescents: study protocol for a randomized controlled trial.

Authors:  Ru Wang; Dongmei Liu; Xueqiang Wang; Weihua Xiao; Nana Wu; Binghong Gao; Peijie Chen
Journal:  Trials       Date:  2014-06-25       Impact factor: 2.279

10.  An Evaluation of Acylated Ghrelin and Obestatin Levels in Childhood Obesity and Their Association with Insulin Resistance, Metabolic Syndrome, and Oxidative Stress.

Authors:  Maryam Razzaghy-Azar; Mitra Nourbakhsh; Abdolreza Pourmoteabed; Mona Nourbakhsh; Davod Ilbeigi; Mohsen Khosravi
Journal:  J Clin Med       Date:  2016-06-23       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.